Saturday, July 11, 2026

Drug profile · INN

delafloxacin

delafloxacin (QUOFENIX) is an FDA-listed pharmaceutical active ingredient.

EMA: approved Antiinfectives for systemic use (J01) J01MA23
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — delafloxacin
Class
Antiinfectives for systemic use (J01)
Route
Patents
0
Programs
1
Data quality
0.83

Quick answer

delafloxacin (QUOFENIX) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN delafloxacin
Brand QUOFENIX
Therapeutic class Antiinfectives for systemic use (J01)
ATC code J01MA23

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. APHP220763 Phase 3 · PARItec · Catheter related bloodstream infections due to Staphylococcu

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is delafloxacin?

delafloxacin (QUOFENIX) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for delafloxacin?

QUOFENIX is a marketed brand name for delafloxacin. Check FDA Drugs@FDA for the current US label holder and prescribing information.